Company News
Clincal Trials and Tribulations Newsletter – May 2022 Edition
Welcome to the May edition of AARDEX Group’s Clinical Trials and Tribulations Newsletter – an aggregated collective of all of the industry’s hottest news and views! Breaking News New Pivotal Data Demonstrates the Clinical Benefit of Roche’s glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma Roche today announced that new pivotal data…
Read MoreIn a world of outcome-based pricing, can you afford to neglect patient adherence?
The emergence of outcome-based contracts in clinical research has placed an additional consideration on the already thorny issue of adherence. When drug companies are paid according to the real-world effectiveness of their products, ensuring people take the medications as prescribed is essential to the all-important return on investment (ROI). Modern approaches, such as digital adherence…
Read MoreAdherence to Medication: The Missing Piece in the Pharmacogenomics Puzzle
If enacted, the US’ Right Drug Dose Now Act will place pharmacogenomics on the main stage of drug development and move us further into the personalized medicine era. By supporting the use of pharmacogenetic testing to prevent adverse events (AEs) and inform the use of therapies that are tailored to a patient’s genetic makeup, it…
Read MoreHarnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research
“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.” – Bernard Vrijens, Scientific Lead, AARDEX® Group Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive…
Read MoreThe Heart of the Matter: The Role of Medication Adherence Tools in Tackling the CVD Epidemic
Despite huge strides in how cardiovascular diseases (CVD) are treated in recent years, the conditions remain among the leading causes of morbidity and mortality worldwide. At least part of the problem is that even the most effective drugs will not work if people do not take them. Yet both in routine practice and in clinical…
Read MoreAARDEX® Group adds etectRx’s Smart Pills to their MEMS® Adherence Hardware ecosystem
The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor smart pill. Liege, Belgium (APRIL 28, 2022) – Belgium-based AARDEX Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s smart pill, the ID-Cap™ System, and AARDEX Group’s MEMS Adherence…
Read MoreExploring the Relationship Between Drug Forgiveness and Patient Adherence
With patient adherence thought to be lower than 50% 1, drug companies are increasingly maximizing dosages to bridge the gap at population scale – but are we overdosing individual patients as a result? The industry’s tendency to always aim for the highest possible dose in the therapeutic window to compensate for missed doses runs the risk…
Read MoreFDA Issues Draft Diversity Guidance to Improve Enrollment of Participants from Underrepresented Patient Populations
Diversity in clinical research is a growing concern for sponsors as many factors can influence how an individual may react to certain drugs: age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background. Thus, if the investigational product is to be scrutinized for safety and efficacy effectively, a diverse population of…
Read MoreOptimizing Study Design to Tackle Protocol Deviations in DCTs
Decentralized Clinical Trials (DCTs) are here to stay, as demonstrated by international regulators’ recent commitments to the model. But while the approach offers a multitude of benefits, from expanding access to increasing cohort diversity, it can also serve to magnify existing protocol deviations such as poor adherence to the dosing regimen. If we are to…
Read MoreHarnessing Digital Health Technology to Bolster Study Power
In a world of big tech, data is king. This slogan is far from news for the Biopharmaceutical Industry, but clinical trials are lengthy, complex, and expensive, meaning precious information isn’t always utilized to its maximum potential. In recent years, a slew of Digital Health Technologies (DHTs), designed to collect and share data remotely, have…
Read More